Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 66Burkitt Lymphoma 26Lymphoma 18Leukemia, Biphenotypic, Acute 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Promyelocytic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm, Residual 5Leukemia, Myeloid, Acute 5Down Syndrome 4Neoplasms 3Leukemia, T-Cell 3Dendritic Cell Sarcoma, Interdigitating 3Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioblastoma 2Thrombocytopenia 1Rare Diseases 1Philadelphia Chromosome 1Ovarian Neoplasms 1Oligodendroglioma 1Neutropenia 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mucositis 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × Mercaptopurine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡